

Staging stenotic oesophageal tumours: Are CT and/or PET enough? Dilate or not?

J. Meenan

Guy's and St. Thomas' Hospital, London

Introduction

Strictered oesophageal tumours are difficult for patient and physician alike. An inability to use standard equipment freely, concentrates the mind as to what the purpose of staging is: what information is sought and why?

Long-term survival with oesophageal and proximal gastric tumours is poor and treatment options for locally advanced disease, unsatisfactory. The scramble for incremental improvements in survival results in a large variation in practice, particularly in respect of using neoadjuvant chemotherapy. Disagreement over general management strategy is both reflected in and moulds discussion on how the staging of stenotic lesions might be achieved. First, to address some of the important peripheral issues.

General considerations

Surgery confers a survival advantage on those with resectable lesions [1,2]. Neoadjuvant chemotherapy might confer a survival

Correspondence: Dr. John Meenan · Department of Gastroenterology · 1st Floor College House · St. Thomas' Hospital · Lambeth Palace Road · London SE1 7EH · Fax: +44 20 71882484 · E-mail: john.meenan@gstt.nhs.uk

Bibliography: Endoscopy 2006; 38 (S1): S8–S12 © Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X · DOI 10.1055/s-2006-946643

advantage, particularly on those who show a clinical response; equally, those with residual positive nodes fare poorly [3,4]. Although the type of cancer under consideration, adenocarcinoma or squamous cell, does not seem to have much impact on survival, the site of the lesion may; the Siewert classification identifies diseases with different prognoses, junctional (Type II) lesions being more associated with node-positive disease and a poorer prognosis [5,6].

Nodal status is central to the staging of oesophageal cancer, as it predicts survival [1,7]. Three confounding factors to describing nodal status need to be addressed in the setting of stenotic lesions: (a) dispute over the accuracy of endoscopic morphology alone in ascribing involvement [8]; (b) lack of a clear definition of what a coeliac node is or represents [9–11]; and extrapolating from this, (c) deficiency of the TNM staging system in respect of what is truly a local node and what is metastatic [12,13]. The presence of micrometastases in pN0 R0-resections (30% of cases) remains a joker in the pack [14].

To start at the beginning: the purpose of staging is to triage to appropriate therapy. There is an absolute need to know whether the lesion is not resectable for reasons of local spread (i.e. T4 or not) or distant disease. There is a qualified need to know whether local lymphatic spread has occurred.

Endosonography

The problem: standard echoendoscopes are stiff and bulky, and tumour dilatation is not without risk. Initial studies reported worryingly high perforation rates [15,16]. More recent figures are considerably better but are not a true reflection of the risks experienced in a wider setting [17–20]. It should be remembered that tumour perforation has a dramatic impact on survival [20].

The combination of sequential dilation and passage of a standard echoendoscope overcomes these difficulties but the risks are higher. The risks associated with oesophageal tumour dilation although less pronounced than previously thought, are not negligible. A prospective audit reported a perforation rate of 6.4% following dilation and/or intubation of malignant strictures compared to 1.1% following dilation of benign strictures [21]. Strict adherence to a graded stepwise dilation protocol (for example, “rule of three”) is advocated for safety, but this often means a second or third dilation session [22]. In addition to the risk and inconvenience to the patient, there are also financial implications for this approach both in terms of additional procedures and disposables. Furthermore, even with this approach, complete staging after dilatation might only be achieved in 62% of cases. (23) A final, important point is that the accuracy of EUS staging following dilatation might be poor, though this was reported in an “early” paper (1995) [15].

Approximately 55% of patients present with dysphagia, though this is not a reliable predictor of being unable to pass a standard echoendoscope [24]. There is a wide variation geographically in the proportion of those found to have stenotic lesions ranging from 25% (USA) to 73% (India) [15,25]. Approximately one-third

of patients from Western countries with oesophageal cancer have stenoses at presentation significant enough to prevent the passage of a standard echoendoscope [26,27].

Before discussing the options for dealing with non-traversable lesions, it is important to consider what information can be gleaned from an incomplete study. Strictureing tumours are rarely less than T3 and positive nodes might be expected in 77%-81% of these [25,28,29]. The lymphatics of the upper two-thirds of the oesophagus drain in a cephalad direction [30]. Sixty percent of involved nodes will be found proximal or level with the tumour, 25% being unreachable distal, yet local, nodes with a further 4.5% being located within 1 cm of the coeliac artery [31]. Applying reductionist logic, the staging problem presented by strictures is limited to relatively few cases, particularly taking into account those unfit for surgery (20%), if neo-adjuvant chemotherapy is given to all operable tumours and if coeliac nodes might be considered local to junctional tumours [32,33].

There are six options for non-traversable malignant strictures: dilation of the stenosis to allow for passage by a standard echoendoscope, use of a catheter ultrasound probe, use of the Olympus MH908 oesophagoprobe, reliance on cross sectional imaging such as CT and positron emission tomography (PET), diagnostic surgery, or, a combination of methods. But, whichever approach is taken, it ought to be done at a specialist centre [34].

Miniproboscopes (catheter probes) are generally of high frequency (12MHz-30MHz), excepting the Fujinon 7.5MHz back-loaded probe (PL-2226B-7.5). The resulting lack of penetration offsets the advantage of small size; although miniprobe sonography can be as accurate as standard echoendosonography, these instruments are not adequate for the staging of large tumours or distant nodes [25,35].

The Olympus (MH908) 7.9 mm non-optical, wire-guided, 7.5MHz, oesophagoprobe showed promising results in small studies [36-38]. Later, larger series (reported in abstract) show this instrument to be a very powerful tool, permitting the complete staging (by morphology) of 95% of cases without the need for dilatation. (25,31) Questions have been raised over the ability of the MH908 to adequately inspect the coeliac trunk on account of restricted tip-deflection, but this worry is not born out in practice [31,35].

Intuitively, it would be reasonable to reserve the oesophagoprobe for those in whom a standard echoendoscope failed to pass. However, as problematic strictures cannot be predicted with any certainty from prior clinical questioning and as EUS equipment may be limited, the use of oesophagoprobe from the outset will improve the staging success and decrease the need for dilation. It might be suggested that the MH908 is the instrument of choice for all oesophageal tumours.

But, what of coeliac nodes and the need to biopsy? This question can only be answered at a local level. There is probably a great difference in the number of lymph nodes to be found in a "normal" mediastinum between both geographic regions and races. It is likely that endemic diseases whether fungal (USA), tuberculosis (developing world) or sarcoid (Afro-Caribbean) lead to varying numbers of detectable nodes; a point noted in Indians under-

going surgery for oesophageal cancer [40]. Anecdotal evidence from the UK (personal data) suggests that if a rounded node is found in a caucasian, in the presence of a tumour, it will almost certainly be positive. Similarly, our experience is that coeliac nodes (those within 1 cm of the coeliac trunk) are only found in 4.5% of cases, a lower figure than that reported by others [40,41]. Taking local conditions into account, application of modified EUS criteria could be applied to minimize the need for FNA [42]. In re-staging tumours following neoadjuvant chemotherapy, EUS-FNA might certainly offer clinically relevant information as non-biopsy FNA in this setting adds little to the information provided by CT [43]. This issue is dealt with elsewhere in this supplement.

CT and PET

Turning to cross-sectional imaging to help with the predicament of strictured lesions. Improvements in computed tomography and greater experience with positron emission tomography (PET) have opened up the possibility of high resolution, dynamic images with the potential for virtual endoscopy. Unfortunately, this bright bauble of imaging tarnishes rapidly.

Leaving aside structural methods of staging and turning to dynamic imaging. Positron Emission Tomography is not tumour specific as benign tissue may accumulate tracer; the commonly used 18F-fluoro-deoxyglucose (FDG), however, is superior to other substrates [44,45]. Early studies showed PET to identify local disease [46,47] though imperfectly [46,48,49] as well as distant metastases [46-50]. Importantly, the histology of the tumour does not confound PET results [51].

Reviewing comparative studies with CT, PET does not identify all primary tumours [52-59]; it does not identify all involved nodes [sensitivity: 30%-80%, median 45%; specificity 82%-100%, median 90% and accuracy 48%-93%, median 80%] [47,48,52,46,65,53,54,62,63,61,60,51,64,58] and nor does it identify all distant metastases [sensitivity 38%-88%, median 64%; specificity 89%-93%, median 90% and accuracy 74%-91%] [47,48,50,52,54,57,58,61-64,66]. But, PET certainly yields additional useful information to that provided by CT [47,48,51,52,54,58,64,66,67]. As one might expect with a dynamic modality, PET demonstrates superior specificity but lower sensitivity than EUS for the identification of loco-regional nodes [54,57,64,68].

Technology gets better. Combined PET/CT holds promise for incremental improvement in staging accuracy. [69-71] But, initial reports evaluating multi-detector CT (with virtual endoscopy) show a persisting inferiority in accuracy to that obtained with PET [72].

The major drawbacks, impairing the accuracy of PET include: a halo effect from the primary tumour hotspot obscuring local nodes [46], a high rate of false-positive hilar node interpretations [63], a tendency to lower sensitivity for nodes in the mid/lower thorax as compared with those in the upper chest, neck or abdomen [55] and spatial/breathing artefact [70]. A false-positive rate of 15% is worrying yet, PET still outperforms EUS-FNA [73,74].

In addition to staging information, the data yielded by PET such as degree of tracer uptake (standardized uptake value, SUV), has been shaken, poked and prodded to reveal prognostic information: an SUV greater than 3–4.5 may predict a less good outcome [55, 75] but, this is not universally reported [76, 77].

In the setting of neo-adjuvant chemo(radio)therapy, the dynamic nature of PET holds promise for guiding treatment. As might be expected, the burden of disease identified by PET (tumour length and number of positive nodes) and resultant upstaging correlate poorly with survival [66, 78]. Early change in tumour 18F-FDG uptake predicts a reduction in tumour size following completion of therapy [79]. In respect of pathological response, a drop in SUV, possibly from a high baseline (> 4) may correlate with favourable post-operative findings [55, 80–82] and/or survival [83, 84]. Again, not all authors are so positive [85, 86]. A meta-analysis of the accuracy of PET, CT and EUS in assessing response to chemotherapy shows equivalence between PET and EUS, both being superior to CT [87].

Overall assessment of the clinical value of PET in the setting of oesophageal cancer shows benefit in terms of useful additional information and the prevention of unnecessary surgery [51, 52, 60, 60, 88–90] although a medium sized trial (n = 56) rains somewhat on this parade [61]. In terms of cost, although the best approach might be PET combined with EUS-FNA, limiting investigations to CT and EUS-FNA might be the most cost effective [91]. Such models however, cannot address the difficulties presented by strictured lesions. So, where does that leave us? PET holds promise in the staging and re-staging of oesophageal tumours but, not as a free standing test.

Other techniques

Other methods to detect lymphatic spread of disease include the search for sentinel lymph nodes whether by cross-sectional or intra-operative lymphangiography [92, 93, 84]. It is not possible to place this approach in any algorithm from the information available.

Towards an algorithm

So, what to do with a stricturing tumour of the oesophagus or oesophago-gastric junction? There are three issues to addressed before imaging: firstly, ascertain the local disease “profile” of this carcinoma (might the majority of nodes, particularly those at the coeliac axis, be considered positive?); secondly, decide whether the patient is fit for surgery and thirdly, decide the criteria for offering neo-adjuvant chemotherapy and subsequent operability (“once T4, always T4”?, what if a coeliac node disappears with therapy? etc). Initial imaging triage should be with CT, or ideally PET/CT. If no disease spread is seen, then EUS using the Olympus oesophagoprobe followed by either acceptance of morphological evidence or graded-dilatation followed by EUS-FNA. In respect of residual strictures following neo-adjuvant chemotherapy, EUS-FNA is required if positive cytology will lead to a non-operable status.

Competing interests: None

References

- el Nakadi I, Houben JJ, Gay F, Closset J, Gelin M, Lambilliotte JP. Does oesophagectomy cure resectable oesophageal cancer? *World J Surg* 1993; 17: 760–764
- Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. *Lancet Oncol* 2005; 6: 864–870
- Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compare neo-adjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. *Am J Surg* 2002; 183: 274–279
- Agarwal B, Swisher S, Ajani J, Kelly K, Komaki RR, Putnam JB Jr, Abu-Hamda E, Moltke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporiciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical oesophageal resection. *Am J Gastroenterol* 2005; 100: 496–497
- Mariette C, Finzi L, Piessen G, Van Seuning I, Triboulet JP. Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. *World J Surg* 2005; 29: 39–45
- Yuasa N, Miyake H, Yamada T, Ebata T, Nimura Y, Hattori T. Clinicopathologic comparison of Siewert type II and III adenocarcinomas of the gastrooesophageal junction. *World J Surg* 2006; 30: 364–371
- Rice TW, Blackstone EH, Adelstein DJ, Zuccaro G Jr, Vargo JJ, Goldblum JR, Rybicki LA, Murthy SC, Decamp MM. N1 esophageal carcinoma: the importance of staging and downstaging. *J Thorac Cardiovasc Surg* 2001; 121: 454–464
- Eloubeidi MA. Routine EUS-guided FNA for preoperative nodal staging in patients with oesophageal carcinoma: is the juice worth the squeeze? *Gastrointest Endosc* 2006; 63: 212–214
- Christie NA, Rice TW, DeCamp MM, Goldblum JR, Adelstein DJ, Zuccaro G Jr, Rybicki LA, Blackstone EH. M1a/M1b esophageal carcinoma: clinical relevance.
- Frizzell B, Sinha D, Williams T, Reed CE, Sherman CA, Turrisi A. Influence of celiac axis lymph nodes in the definitive treatment of oesophageal cancer. *Am J Clin Oncol* 2003; 26: 215–220
- Lerut T, Coosemans W, Decker G, De Leyn P, Moons J, Nafteux P, Van Raemdonck D. Extended surgery for cancer of the oesophagus and gastrooesophageal junction. *J Surg Res* 2004; 117: 58–63
- Rice TW, Blackstone EH, Rybicki LA, Adelstein DJ, Murthy SC, Decamp MM, Goldblum JR. Refining oesophageal cancer staging. *J Thorac Cardiovasc Surg* 2003; 125: 992–993
- Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Shimada H. Developing an appropriate staging system for esophageal carcinoma. *J Am Coll Surg* 2005; 201: 884–890
- Heeren PA, Kelder W, Blodeel I, van Westreenen HL, Hollema, Plukker JT. prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. *Eur J Surg Oncol* 2005; 31: 270–276
- Catalano MF, Van Dam J, Sivak MV Jr. Malignant esophageal strictures: staging accuracy of endoscopic ultrasonography. *Gastrointest Endosc* 1995; 41: 535–539
- Van Dam J, Rice TW, Catalano MF, Kirby T, Sivak MV Jr. High-grade malignant stricture is predictive of esophageal tumor stage: risks of endosonographic evaluation. *Cancer* 1993; 71: 2910–2917
- Wallace MB, Hawes RH, Sahai AV, Van Velse A, Hoffman BJ. Dilation of malignant esophageal stenosis to allow EUS guided fine-needle aspiration: safety and effect on patient management. *Gastrointest Endosc* 2000; 51: 309–313
- Pfau PR, Ginsberg GG, Lew RJ, Faigel DO, Smith DB, Kochman ML. Esophageal dilation for endosonographic evaluation of malignant esophageal strictures is safe and effective. *Am J Gastroenterol* 2000; 95: 2813–2815
- Kallimanis GE, Gupta PK, Al-Kawas FH, Tio LT, Benjamin SB, Bertagnolli ME et al. Endoscopic ultrasound for staging esophageal cancer, with or without dilation, is clinically important and safe. *Gastrointest Endosc* 1995; 41: 540–546
- Jethwa P, Lala A, Powell J, McConkey CC, Gillison EW, Spychal RT. A regional audit of iatrogenic perforation of tumours of the oesophagus and cardia. *Aliment Pharmacol Ther* 2005; 21: 479–484
- Quine MA, Bell GD, McCloy RF, Matthews HR. Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England. *Br J Surg* 1995; 82: 530–533

- 22 Langdon DF. The rule of three in oesophageal dilatation. *Gastrointest Endosc* 1997; 45: 111
- 23 Vazquez-Sequeiros E, Wiersema MJ, Clain JE, Norton ID, Levy MJ, Romero Y, Salomao D, Dierkhising R. Impact of lymph node staging on therapy of oesophageal carcinoma. *Gastroenterol* 2003; 125: 1626–1635
- 24 Schlansky B, Dimarino AJ Jr, Loren D, Infantolino A, Kowalski T, Cohen S. A survey of oesophageal cancer: pathology, stage, and clinical presentation. *Aliment Pharmacol Ther* 2006; 23: 587–589
- 25 Dhir V, Mohandas KM, Mehta S, Shastri Y, Sharma S, Deshpande RK. Endoscopic ultrasound staging of stenotic oesophageal cancer: miniprobe, dilation, MH908 or helical computed tomography (CT)? *Gastrointest Endosc* 2002; 56: S108
- 26 Dittler HJ, Siewert JR. Role of endoscopic ultrasonography in esophageal carcinoma. *Endoscopy* 1993; 25: 156–161
- 27 Grimm H, Binmoeller KF, Hamper K, Koch J, Henne-Bruns D, Soehendra N. Endosonography for the preoperative locoregional staging of esophageal and gastric cancer. *Endoscopy* 1993; 25: 224–230
- 28 Rice TW, Zucarro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Oesophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. *Ann Thorac Surg* 1998; 65: 787–792
- 29 Koufuji K, Shirouzu K, Aoyagi K, Yano S, Miyagi M, Imaizumi T, Takeda J. Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction. *Kurume Med J* 2005; 52: 73–79
- 30 Sharma A, Fidias P, Hayman LA, Loomis SL, Taber KH, Aquino SL. Patterns of lymphadenopathy in thoracic malignancies. *Radiographics* 2004; 24: 419–434
- 31 Vu C, Doig LA, Anderson S, Tsang S, Meenan J. Large series Western European experience with the Olympus MH908 slim-probe shows greater complete staging of oesophageal cancer without the need for dilatation. *Gastrointest Endosc* 2004; 59: AB213
- 32 Gockel I, Kneist W, Junginger T. Incurable oesophageal cancer: patterns of tumor spread and therapeutic consequences. *World J Surg* 2006; 30: 183–190
- 33 Medical Research Council Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. *Lancet* 2002; 359: 1727–1733
- 34 van Vliet EP, Eijkemans MJ, Kuipers EJ, Hermans JJ, Steyberg EW, Tilanus HW, van der Gaast A, Siersma PD. A comparison between low volume referring regional centers and a high volume referral centre in quality of preoperative metastasis detection in oesophageal carcinoma. *Am J Gastroenterol* 2006; 101: 234–242
- 35 Menzel J, Hoepffner J, Nottberg H, Schulz C, Senninger N, Domschke W. Preoperative staging of esophageal carcinoma: miniprobe sonography versus conventional endoscopic ultrasound in a prospectively histopathologically verified study. *Endoscopy* 1999; 31: 291–297
- 36 Binmoeller KF, Seifert H, Seitz U, Izbicki JR, Kida M, Soehendra N. Ultrasonic esophagoprobe for TNM staging of highly stenosing esophageal carcinoma. *Gastrointest Endosc* 1995; 41: 547–552
- 37 Mallery S, Van Dam J. Increased rate of complete EUS staging of patients with esophageal cancer using the non-optical, wire-guided echoendoscope. *Gastrointest Endosc* 1999; 50: 53–57
- 38 Bowrey DJ, Clark GWB, Roberts SA, Maughan TS, Hawthorne AB, Williams GT et al. Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe. *Diseases of the Esophagus* 1999; 12: 258–263
- 39 Sharma D, Thakur A, Toppo S, Chandrakar SK. Lymph node counts in Indians in relation to lymphadenectomy for carcinoma of the esophagus and stomach. *Asian J Surg* 2005; 28: 116–120
- 40 Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. *Cancer* 1995; 76: 1120–1125
- 41 Pfau PR, Ginsberg GG, Lew RJ, Brensinger CM, Kochman ML. EUS predictors of long-term survival in esophageal carcinoma. *Gastrointest Endosc* 2001; 53: 463–469
- 42 Vazquez-Sequeiros E, Levy MJ, Clain JE, Schwartz DA, Harewood GC, Salomao D, Wiersema MJ. Routine v's selective EUS-guided FNA approach for preoperative nodal staging of oesophageal carcinoma. *Gastrointest Endosc* 2006; 63: 204–211
- 43 Mesenas S, Vu C, McStay M, Doig LA, Meenan J. Radial EUS for re-staging oesophageal cancer after neoadjuvant chemotherapy predicts survival but not resectability: a large resection controlled study. *Gastrointest Endosc*, 2006 (DDW 2006, In press)
- 44 van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, Plukker JT. Comparison of 18F-FLT PET and 18F-FDG PET in oesophageal cancer. *J Nucl Med* 2005; 46: 400–404
- 45 Jager PL, Que TH, Vaalburg W, Pruijm J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer? *Eur J Nucl Med* 2001; 28: 1845–1849
- 46 Rankin SC, Taylor H, Cook GJR, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. *Clinical Radiol* 1998; 53: 659–665
- 47 Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD. Staging of oesophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. *Am J Roentgenol* 1997; 168: 417–424
- 48 Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, Ferson PF, Keenan RJ, Belani CP. Role of positron emission tomography in staging oesophageal cancer. *Ann Thorac Surg* 1997; 64: 765–769
- 49 Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, Urso GK, Dacheville MA, Townsend DW. Whole-body FDG positron emission tomography imaging for staging esophageal cancer, comparison with computed tomography. *Clin Nucl Med* 2000; 25: 882–887
- 50 Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in oesophageal cancer: 100 consecutive positron emission tomography scans. *Ann Thorac Surg* 1999; 68: 1133–1136
- 51 Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in oesophageal cancer. Incremental value over computed tomography. *Clin Positron Imaging* 1999; 2: 255–260
- 52 Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging oesophageal and gastrooesophageal malignancy. *Br J Cancer* 1998; 78: 521–527
- 53 Montravers F, Grahek D, Kerrou K, de Beco V, Younsi N, Barrier A, LKacaine F, Huguier M, Talbot JN. 14.FDG CDET (2D dual-head coincidence gamma camera) in the primary staging of oesophageal cancer. *Histopathological correlation. Clin Positron Imaging* 2000; 3: 168
- 54 Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Martelmans L. Utility of positron emission tomography for the staging of patients with potentially operable oesophageal carcinoma. *J Clin Oncol* 2000; 18: 3202–3210
- 55 Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsujada K, Oriuchi N, Inoue T, Endo K. Comparison between positron emission tomography and computed tomography in the assessment of oesophageal carcinoma. *Cancer* 2002; 94: 921–928
- 56 Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, Larson SM. FDG-PET in oesophageal cancer. Incremental value over computed tomography. *Clin Positron Imaging* 1999; 2: 255–260
- 57 Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy of positron emission tomography, computed tomography and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. *Ann Surg Oncol* 2003; 10: 954–960
- 58 Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of oesophageal carcinoma. *Cancer* 2005; 103: 148–156
- 59 Meenan J, Vu C, Rankin S, Harper P. A prospective, blinded trial comparing the accuracy of PET, EUS and CT with resection pathology in the staging of oesophageal cancer following neo-adjuvant chemotherapy. *Gastrointest Endosc* 2004; 59: AB214
- 60 Sihvo EI, Rasanen JV, Knuuti MJ, Minn HR, Luostarinen ME, Viljanen T, Farkkila MA, Salo JA. Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in loco-regional disease. *Gastrointest Surg* 2004; 8: 988–996
- 61 Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T. Positron emission tomography for staging oesophageal cancer: does it lead to a different therapeutic approach? *World J Surg* 2003; 27: 1105–1112
- 62 Kneist W, Schreckenberger M, Bartenstein P, Menzel C, Oberholzer K, Junginger T. Prospective evaluation of positron emission tomography in the preoperative staging of oesophageal cancer. *Arch Surg* 2004; 139: 1043–1049

- ⁶³ Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection. A prospective study. *Radiology* 2003; 227: 764–770
- ⁶⁴ Lowe VJ, Booya F, Fletcher JG, Nathan N, Jensen E, Mullan B, Rohren E, Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography and endoscopic ultrasound in the initial staging of patients with oesophageal cancer. *Mol Imaging Biol* 2005; 7: 422–430
- ⁶⁵ McAteer D, Wallis F, Couper G, Norton M, Welch A, Bruce D, Park K, Nicolson M, Gilbert FJ, Sharp P. Evaluation of 18F FDG positron emission tomography in gastric and oesophageal carcinoma. *Br J Radiol* 1999; 72: 525–529
- ⁶⁶ Blackstock AW, Farmer MR, Lovato J, Mishra G, Melin SA, Oaks T, Aklilu M, Clark PB, Levine EA. A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced oesophageal cancer. *Int J Radiat Oncol Biol Phys* 2006; 64: 455–460
- ⁶⁷ Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy of positron emission tomography, computed tomography and endoscopic ultrasound in staging of adenocarcinoma of the oesophagus and esophagogastric junction. *Ann Surg Oncol* 2003; 10: 954–960
- ⁶⁸ Kanski A, Doss M, Milestone B, Haluszka O, Hanlon A, Freedman G, Adler L. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment planning process for oesophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2005; 61: 1123–1128
- ⁶⁹ Bar-Shalom R, Guralnik L, Tsalic M, Leiderman M, Frenkel A, Gaitini D, Ben-Nun A, Keidat Z, Israel O. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. *Eur J Nucl Med Mol Imaging* 2005; 32: 918–924
- ⁷⁰ Pan T, Mawlawi O, Nehmeh SA, Erdi YE, Luo D, Liu HH, Castollo R, Mohan R, Liao Z, Macapinlac HA. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. *J Nucl Med* 2005; 46: 1481–1487
- ⁷¹ Moureau-Zabotto L, Touboul E, Lerouge D, Deniaud-Alexandre E, Grahek D, Foulquier JN, Petegnief Y, Gres B, El Balaa H, Kerrou K, Montravers F, Keraudy K, Turet E, Gendre JP, Grange JD, Houry S, Talbot JN. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformational radiotherapy in oesophageal carcinoma. *Int J Radiat Oncol Biol Phys* 2005; 63: 340–345
- ⁷² Onbas O, Eroglu A, Kantarci M, Polat P, Alper F, Karaoglanoglu N, Okur A. Preoperative staging of oesophageal carcinoma with multidetector CT and virtual endoscopy. *Eur J Radiol* 2006; 57: 90–95
- ⁷³ van Westreenen HL, Heeren PA, Jager PL, van Dullemen HM, Groen H, Plukker JT. Pitfalls of positive findings in staging esophageal cancer with F-18-fluorodeoxyglucose positron emission tomography. *Ann Surg Oncol* 2003; 10: 1100–1105
- ⁷⁴ Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine needle aspiration, integrated positron emission tomography with computed tomography and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. *J Thorac Cardiovasc Surg* 2005; 129: 1232–1241
- ⁷⁵ Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, Larson S, Rusch V. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after oesophageal adenocarcinoma resection. *Ann Thorac Surg* 2006; 81: 1076–1081
- ⁷⁶ Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Lomaki R, Ajani JA. Value of baseline positron emission tomography for predicting overall survival in patients with nonmetastatic oesophageal or gastroesophageal junction carcinoma. *Cancer* 2005; 104: 1620–1626
- ⁷⁷ Stahl A, Stollfuss J, Ott K, Wieder H, Fink U, Schwaiger M, Weber WA. FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. *Nuklearmedizin* 2005; 44: 249–255
- ⁷⁸ Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, Choi Y, Choe YS, Kim BT. 18F-FDG PET in patients with oesophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. *J Nucl Med* 2004; 45: 1843–1850
- ⁷⁹ Wieder HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ, Ziegler S, Siewer JR, Schwaiger M, Weber WA. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. *J Nucl Med* 2005; 46: 2029–2034
- ⁸⁰ Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song SY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable oesophageal cancer. *Int J Radiat Oncol Biol Phys* 2005; 63: 1052–1059
- ⁸¹ Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M. Neoadjuvant therapy of oesophageal squamous cell carcinoma: response evaluation by positron emission tomography. *Ann Surg* 2001; 233: 300–309
- ⁸² Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JBJr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. *Cancer* 2004; 101: 1776–1785
- ⁸³ Swisher SG, Maish M, Erasmus J, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JBJr, Rice DC, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer. *Ann Thorac Surg* 2004; 78: 1152–1160
- ⁸⁴ Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch Y. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003; 21: 428–432
- ⁸⁵ Brink L, Hentschel M, Bley TA, Walch A, Mix M, Klemaier M, Moser E, Imdahl A. Effects of neo-adjuvant radio-chemotherapy on 18F-FDG-PET in oesophageal carcinoma. *Eur J Surg Oncol* 2004; 30: 544–550
- ⁸⁶ Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with oesophageal cancer. *Mol Imaging Biol* 2002; 4: 310–310
- ⁸⁷ Westerterp M, van Westreenen HL, Hoekstra OS, Stoker J, Fockens P, Jager PL, Van Eck-Smit BLF, Plukker JT, van Lanschot JB, Sloof GW. Oesophageal cancer: CT, Endoscopic US and FDG PET for assessment of response to neoadjuvant therapy- systemic review. *Radiology* 2005; 236: 841–851
- ⁸⁸ Duong CP, Demetriou H, Weih L, Thompson A, Williams D, Thomas RJ, Hicks RJ. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. *Eur J Nucl Med Mol Imaging* 2006; 10: 1–11
- ⁸⁹ Imdahl A, Hentschel M, Kleimaier M, Hopt UT, Brink L. Impact of FDG-PET for staging of oesophageal cancer. *Langenbecks Arch Surg* 2004; 398: 283–288
- ⁹⁰ van Westreenen HL, Heeren PA, van Dullemen HM, van der Jagt KJ, Jager PL, Groen H, Plukker JT. Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of oesophageal cancer prevents unnecessary surgical explorations. *J Gastrointest Surg* 2005; 8: 54–61
- ⁹¹ Wallace MB, Nietert PJ, Earle C, Krasna MJ, Hawes RH, Hoffman BJ, Reed CE. An analysis of multiple staging management strategies for carcinoma of the oesophagus: computed tomography, endoscopic ultrasound, positron emission tomography and thoracic/laparoscopy. *Ann Thorac Surg* 2002; 74: 1026–1032
- ⁹² Hayashi H, Tangoku A, Suga K, Shimizu K, Ueda K, Yoshino S, Abe T, Sato T, Matsunaga N, Oka M. Ct lymphography-navigated sentinel lymph node biopsy in patients with superficial oesophageal cancer. *Surgery* 2006; 139: 225–235
- ⁹³ Kitagawa Y, Fujii H, Mukai M, Kubo A, Kitajima M. Sentinel lymph node mapping in oesophageal and gastric cancer. *Cancer Treat Res* 2005; 127: 123–139
- ⁹⁴ Cense HA, Sloof GW, Klaase JM, Bergman JJ, van Hemert FJ, Fockens P, van Lanschot JJ. Lymphatic drainage routes of the gastric cardia visualized by lymphoscintigraphy. *J Nucl Med* 2004; 45: 247–252